Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

141. The incidence of the main adverse events of Simvastatin among patients with coronary heart disease, hyperlipidemia or type 2 diabetes mellitus: systematic review and meta-analysis based on RCTs and observational studies

The incidence of the main adverse events of Simvastatin among patients with coronary heart disease, hyperlipidemia or type 2 diabetes mellitus: systematic review and meta-analysis based on RCTs and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

142. Meta-analysis comparing the rate of cardiovascular adverse events based on dialysis modality

Meta-analysis comparing the rate of cardiovascular adverse events based on dialysis modality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

143. Adverse events of nucleos(t)ide analogs for chronic hepatitis B: a systematic review

Adverse events of nucleos(t)ide analogs for chronic hepatitis B: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

144. Osmotic diuresis adverse events of sodium glucose cotransporter 2 (SGLT2) inhibitors: meta-analysis of randomized double-blind placebo-controlled clinical trials

Osmotic diuresis adverse events of sodium glucose cotransporter 2 (SGLT2) inhibitors: meta-analysis of randomized double-blind placebo-controlled clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

145. Network meta-analysis quantifying effects of GLP1 receptor agonists and SGLT2 inhibitors on cardiovascular risk factors, microvascular and macrovascular outcomes, adverse events, and mortality

Network meta-analysis quantifying effects of GLP1 receptor agonists and SGLT2 inhibitors on cardiovascular risk factors, microvascular and macrovascular outcomes, adverse events, and mortality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2018 PROSPERO

146. Risk of adverse events across blood pressure levels: an overview of systematic review, systematic review and meta-analysis

Risk of adverse events across blood pressure levels: an overview of systematic review, systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

147. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification

Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual (...) for the revised WHO classification, 2nd ed View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization . (‎2018)‎. Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification, 2nd ed. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description ix, 48 p. ISBN 9789241513654 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization. Regional

2018 WHO

148. Do checklists and bundles reduce adverse events surrounding endotracheal intubation? A systematic review

Do checklists and bundles reduce adverse events surrounding endotracheal intubation? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

149. Effectiveness and adverse events of hypodermoclysis in fluid infusion for child rehydration: systematic review protocol

Effectiveness and adverse events of hypodermoclysis in fluid infusion for child rehydration: systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

150. Cardiovascular adverse events of combination therapy versus monotherapy for adults with non-neurogenic overactive bladder

Cardiovascular adverse events of combination therapy versus monotherapy for adults with non-neurogenic overactive bladder Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

151. A before-after study on the impact of computerised electronic order entry (CPOE) on adverse drug events in hospitalised patients

A before-after study on the impact of computerised electronic order entry (CPOE) on adverse drug events in hospitalised patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

152. Cardiovascular adverse events in patients with melanoma treated with BRAF/MEK inhibitors

Cardiovascular adverse events in patients with melanoma treated with BRAF/MEK inhibitors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

153. Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomized controlled trials comparing with placebo, adjuvants, and other vaccines

Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomized controlled trials comparing with placebo, adjuvants, and other vaccines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

154. Cardiovascular adverse events associated with Integrase Inhibitor, Dolutegravir (DTG) for the treatment of HIV: a systematic review and meta-analysis of randomized controlled trials

Cardiovascular adverse events associated with Integrase Inhibitor, Dolutegravir (DTG) for the treatment of HIV: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

155. Does the use of ambulatory oxygen during activity reduce the incidence of adverse events in patients with stable chronic obstructive pulmonary disease? A systematic review

Does the use of ambulatory oxygen during activity reduce the incidence of adverse events in patients with stable chronic obstructive pulmonary disease? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

156. Gender differences in long-term all-cause mortality and major adverse cardiovascular events among patients with symptomatic peripheral arterial disease: a systematic review and meta-analysis

Gender differences in long-term all-cause mortality and major adverse cardiovascular events among patients with symptomatic peripheral arterial disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2018 PROSPERO

157. An overview of statistical methods developed to analyse adverse events in clinical trials: protocol for a methodological review

An overview of statistical methods developed to analyse adverse events in clinical trials: protocol for a methodological review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

158. Relative risk of and determinants for adverse events of anti-IgE drugs: a systematic review and meta-analysis of randomized controlled trials

Relative risk of and determinants for adverse events of anti-IgE drugs: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

159. Systematic review and meta-analysis on management of adverse events of regorafenib: determination of outcomes and association with risk factors

Systematic review and meta-analysis on management of adverse events of regorafenib: determination of outcomes and association with risk factors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

160. Serious adverse events associated with PCSK9 inhibitors: a meta-analysis of placebo-controlled trials

Serious adverse events associated with PCSK9 inhibitors: a meta-analysis of placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO